FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282973801> ?p ?o ?g. }

• W4282973801 endingPage "3481" @default.
• W4282973801 startingPage "3481" @default.
• W4282973801 abstract "Abstract Alofanib is a potent, small molecule, allosteric inhibitor that binds to the non-active extracellular site of IIIc and IIIb FGFR2 isoforms. Phase 1b clinical study (RPT835GC1B) met its primary endpoints and recommended phase 2 dose was described early. Here, we present pharmacokinetics (PK) and results of biomarker analysis. Alofanib was administered daily intravenously for 5-days followed by a 2-day interval (rest). There were five dose levels using a 3 + 3 design. 21 patients have been enrolled in the study. Patients were Caucasian (100%), predominantly male (71%), 67% had 2 and more metastatic sites, including liver (43%) and bone (14.3%) metastases, 19% had ECOG PS 2, and were heavily pretreated (86% had previous 3 and more lines of therapy). The PK and biomarker analysis set included 18 patients. FGFR2 amplification was accessed by FISH with ZytoLight SPEC FGFR2/CEN 10 Dual Color Probe and FGFR2 expression was accessed by IHC with antibody 1G3 (Abcam (ab 5820). Table summarizes PK data. The geometric mean values of Cmax, AUC0-t, T1/2, Vd increased and CL, Kel decreased approximately dose-proportionally after single dosing, similar to previous preclinical studies. The decrease in the mean value of the Vd for a dose of 350 mg/m2 may be associated with a significant increase in AUC0-t. No correlations between PK values and objective response rate (n=2; 9.5%), progression-free (median 3.63 months (95% CI, 1.58 - 5.68) and overall (median 7.0 months (3.82 - 10.18) survival as well as in patients with liver metastases were found (all P&gt;0.1). A positive FGFR2 IHC expression was observed in all tumor cells and a weak positive reaction in normal epithelium. FGFR2 amplification was confirmed by FISH in 1 (5.6%) patient.Alofanib PK in a gastric patient population is well characterized, supporting the use of a once-daily 350 mg/m2 dose. In further studies, the evaluation of FGFR2 amplification seems to be important. Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 50 mg/m2 100 mg/m2 165 mg/m2 250 mg/m2 350 mg/m2 Cmax, mcg/ml (CV%) 21.4 (32.3) 23.7 (18.4) 44.7 (15.5) 72.8 (64.3) 145.9 (42.7) AUC0-t, mcg*h/ml (CV%) 2.3 (31.9) 6.6 (14.2) 13.3 (49.9) 23.8 (8.7) 74.0 (57.5) Vd, ml/m2 (CV%) 4006.1 (28.3) 4907.5 (14.7) 5676.8 (26.6) 6686.7 (11) 3823.0 (63.8) CL, ml/h/m2 (SD) 19609.5 (7740) 14028.2 (1990) 11910.5 (8740) 10011.0 (827) 4183.0 (2420) Kel, 1/h (CV%) 4.9 (15.3) 2.9 (2.8) 2.1 (41.2) 1.5 (3.8) 1.1 (47.0) T1/2, h (SD) 0.1 (0.024) 0.2 (0.01) 0.3 (0.118) 0.5 (0.0171) 0.6 (0.293) Citation Format: Grigory Raskin, Vasily Kazey, Svetlana Gorbacheva, Aiyyna Nikiforova, Galina Statsenko, Elena Artamonova, Liubov Vladimirova, Natalia Besova, Anastasia Mochalova, Ivan Rykov, Vladimir Moiseyenko, Igor Utyashev, Sergei Iugai, Nadezhda Dragun, Dmitry Reznikov, Evgenia Gavrilova, Sergei Tjulandin, Ilya Tsimafeyeu. Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3481." @default.
• W4282973801 created "2022-06-17" @default.
• W4282973801 creator A5000644939 @default.
• W4282973801 creator A5000739763 @default.
• W4282973801 creator A5009508647 @default.
• W4282973801 creator A5012700479 @default.
• W4282973801 creator A5021233486 @default.
• W4282973801 creator A5022023816 @default.
• W4282973801 creator A5022483415 @default.
• W4282973801 creator A5022911908 @default.
• W4282973801 creator A5027650726 @default.
• W4282973801 creator A5035686789 @default.
• W4282973801 creator A5038833324 @default.
• W4282973801 creator A5045880367 @default.
• W4282973801 creator A5053827199 @default.
• W4282973801 creator A5059463927 @default.
• W4282973801 creator A5067086538 @default.
• W4282973801 creator A5070988170 @default.
• W4282973801 creator A5077585209 @default.
• W4282973801 creator A5081553012 @default.
• W4282973801 date "2022-06-15" @default.
• W4282973801 modified "2023-10-07" @default.
• W4282973801 title "Abstract 3481: Pharmacokinetics of alofanib and biomarker analysis in patients with advanced gastric cancer: A phase 1b study" @default.
• W4282973801 doi "https://doi.org/10.1158/1538-7445.am2022-3481" @default.
• W4282973801 hasPublicationYear "2022" @default.
• W4282973801 type Work @default.
• W4282973801 citedByCount "1" @default.
• W4282973801 countsByYear W42829738012023 @default.
• W4282973801 crossrefType "journal-article" @default.
• W4282973801 hasAuthorship W4282973801A5000644939 @default.
• W4282973801 hasAuthorship W4282973801A5000739763 @default.
• W4282973801 hasAuthorship W4282973801A5009508647 @default.
• W4282973801 hasAuthorship W4282973801A5012700479 @default.
• W4282973801 hasAuthorship W4282973801A5021233486 @default.
• W4282973801 hasAuthorship W4282973801A5022023816 @default.
• W4282973801 hasAuthorship W4282973801A5022483415 @default.
• W4282973801 hasAuthorship W4282973801A5022911908 @default.
• W4282973801 hasAuthorship W4282973801A5027650726 @default.
• W4282973801 hasAuthorship W4282973801A5035686789 @default.
• W4282973801 hasAuthorship W4282973801A5038833324 @default.
• W4282973801 hasAuthorship W4282973801A5045880367 @default.
• W4282973801 hasAuthorship W4282973801A5053827199 @default.
• W4282973801 hasAuthorship W4282973801A5059463927 @default.
• W4282973801 hasAuthorship W4282973801A5067086538 @default.
• W4282973801 hasAuthorship W4282973801A5070988170 @default.
• W4282973801 hasAuthorship W4282973801A5077585209 @default.
• W4282973801 hasAuthorship W4282973801A5081553012 @default.
• W4282973801 hasConcept C112705442 @default.
• W4282973801 hasConcept C121608353 @default.
• W4282973801 hasConcept C126322002 @default.
• W4282973801 hasConcept C126894567 @default.
• W4282973801 hasConcept C143998085 @default.
• W4282973801 hasConcept C22979827 @default.
• W4282973801 hasConcept C2777288759 @default.
• W4282973801 hasConcept C2781197716 @default.
• W4282973801 hasConcept C44249647 @default.
• W4282973801 hasConcept C55493867 @default.
• W4282973801 hasConcept C71924100 @default.
• W4282973801 hasConcept C86803240 @default.
• W4282973801 hasConcept C90924648 @default.
• W4282973801 hasConcept C98274493 @default.
• W4282973801 hasConceptScore W4282973801C112705442 @default.
• W4282973801 hasConceptScore W4282973801C121608353 @default.
• W4282973801 hasConceptScore W4282973801C126322002 @default.
• W4282973801 hasConceptScore W4282973801C126894567 @default.
• W4282973801 hasConceptScore W4282973801C143998085 @default.
• W4282973801 hasConceptScore W4282973801C22979827 @default.
• W4282973801 hasConceptScore W4282973801C2777288759 @default.
• W4282973801 hasConceptScore W4282973801C2781197716 @default.
• W4282973801 hasConceptScore W4282973801C44249647 @default.
• W4282973801 hasConceptScore W4282973801C55493867 @default.
• W4282973801 hasConceptScore W4282973801C71924100 @default.
• W4282973801 hasConceptScore W4282973801C86803240 @default.
• W4282973801 hasConceptScore W4282973801C90924648 @default.
• W4282973801 hasConceptScore W4282973801C98274493 @default.
• W4282973801 hasIssue "12_Supplement" @default.
• W4282973801 hasLocation W42829738011 @default.
• W4282973801 hasOpenAccess W4282973801 @default.
• W4282973801 hasPrimaryLocation W42829738011 @default.
• W4282973801 hasRelatedWork W2002127959 @default.
• W4282973801 hasRelatedWork W2002994412 @default.
• W4282973801 hasRelatedWork W2004706469 @default.
• W4282973801 hasRelatedWork W2080969318 @default.
• W4282973801 hasRelatedWork W2379280247 @default.
• W4282973801 hasRelatedWork W2604417740 @default.
• W4282973801 hasRelatedWork W2899072855 @default.
• W4282973801 hasRelatedWork W2942467058 @default.
• W4282973801 hasRelatedWork W2972898444 @default.
• W4282973801 hasRelatedWork W3151787567 @default.
• W4282973801 hasVolume "82" @default.
• W4282973801 isParatext "false" @default.
• W4282973801 isRetracted "false" @default.
• W4282973801 workType "article" @default.